Yueksel Karaaslan - Bayer Aktiengesellscha Member of the Supervisory Board

BAYZF Stock  USD 30.79  1.38  4.69%   

Executive

Mr. Yueksel Karaaslan was Member of the Supervisory Board and Employee Representative of Bayer Aktiengesellschaft since April 27, 2012. He is Member of the Human Resources Committee at the Company. He is Chairman of the Works Council of the Berlin site, Vice Chairman of the Bayer Central Works Council and Chairman of the Bayer Group Works Council. since 2012.
Age 47
Tenure 12 years
Phone49 214 30 1
Webhttps://www.bayer.com

Bayer Aktiengesellscha Management Efficiency

The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer Aktiengesellscha's management efficiency ratios could be used to measure how well Bayer Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 35.55 B in total debt with debt to equity ratio (D/E) of 1.17, which is about average as compared to similar companies. Bayer Aktiengesellschaft has a current ratio of 1.16, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Bayer Aktiengesellscha until it has trouble settling it off, either with new capital or with free cash flow. So, Bayer Aktiengesellscha's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bayer Aktiengesellschaft sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bayer to invest in growth at high rates of return. When we think about Bayer Aktiengesellscha's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Steffen LangNovartis AG ADR
57
Duane ArsdaleJohnson Johnson
N/A
Andrin OswaldNovartis AG ADR
41
Steven BaertNovartis AG ADR
45
Peter KornickerNovartis AG
N/A
F HoffmannRoche Holding AG
N/A
John ReedRoche Holding AG
59
Gottlieb KellerRoche Holding AG
64
Peter DannenbaumMerck Company
N/A
Peter KornickerNovartis AG ADR
N/A
Bertrand BodsonNovartis AG
43
Erwin VanhaeckeNovartis AG
N/A
Cristina WilburRoche Holding AG
56
Michele GalenNovartis AG ADR
N/A
Michael VarneyRoche Holding AG
60
William WintersNovartis AG ADR
60
Brian McNamaraNovartis AG
47
John ReedRoche Holding
59
Eric DozierEli Lilly And
57
Jefrey PottAstraZeneca PLC
N/A
Verena BrinerNovartis AG ADR
64
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Ag is traded on OTC Exchange in the United States. Bayer Aktiengesellschaft [BAYZF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Bayer Aktiengesellschaft Leadership Team

Elected by the shareholders, the Bayer Aktiengesellscha's board of directors comprises two types of representatives: Bayer Aktiengesellscha inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer Aktiengesellscha's management team and ensure that shareholders' interests are well served. Bayer Aktiengesellscha's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer Aktiengesellscha's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oliver Maier, Head Relations
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division
Thomas Fischer, Member of the Supervisory Board
Marijn Dekkers, Chairman of Management Board and CEO
Helmut Panke, Member of the Supervisory Board
Reiner Hoffmann, Member of the Supervisory Board
Sue Rataj, Member of the Supervisory Board
Petra ReinboldKnape, Member of the Supervisory Board
Dieter Weinand, Member of the Management Board and Head of the Pharmaceuticals Division, North America Region
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board
Sarena Lin, Labor Officer
Simone BagelTrah, Member of the Supervisory Board
Michael SchmidtKiessling, Member of the Supervisory Board
ErnstLudwig Winnacker, Member of the Supervisory Board
Colleen Goggins, Member of the Supervisory Board
Heinz Webers, Member of the Supervisory Board
Johanna Faber, Member of the Supervisory Board
Frank Loellgen, Member of the Supervisory Board
Andre Broich, Member of the Supervisory Board
Liam Condon, Member of Management Board and CEO of Bayer Cropscience
Rodrigo Santos, Member Division
Patrick Thomas, CEO, Bayer MaterialScience
Yueksel Karaaslan, Member of the Supervisory Board
Erica Mann, Member of the Management Board, Head of the Consumer Health Division
Norbert Bischofberger, Member of the Supervisory Board
Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability
Michael Koenig, Member of the Management Board responsible for Human Resources
Thomas Win, Vice Chairman of the Supervisory Board
Jennifer Brendelto, Vice President - Communications of the Consumer Health Division
Heike Hausfeld, Member of the Supervisory Board
Peter Hausmann, Member of the Supervisory Board
Detlef Rennings, Member of the Supervisory Board
Werner Wenning, Chairman of the Supervisory Board
Michael Preuss, Gov Communications
Kemal Malik, Member of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer Healthcare
Petra Kronen, Member of the Supervisory Board
Oliver Zuehlke, Member of the Supervisory Board
Thomas Elsner, Member of the Supervisory Board
Alexander Rosar, Head of Investor Relations
Wolfgang Nickl, CFO, Member of the Management Board
Paul Achleitner, Member of the Supervisory Board
Klaus Sturany, Independent Member of the Supervisory Board
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division
Thomas Ebeling, Member of the Supervisory Board
Johannes Dietsch, CFO and Member of Management Board
Gabriel Harnier, Patents Law
Norbert Winkeljohann, Independent Member of the Supervisory Board
Clemens Boersig, Member of the Supervisory Board
Juergen Beunink, Interim Head of Investor Relations
Otmar Wiestler, Member of the Supervisory Board
Sabine Schaab, Member of the Supervisory Board
BerndPeter Bier, Head Taxes
Wolfgang Plischke, Member of the Supervisory Board

Bayer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer Aktiengesellscha a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Bayer Aktiengesellscha

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer Aktiengesellscha position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer Aktiengesellscha will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bayer Pink Sheet

  0.86RHHBF Roche Holding AGPairCorr
  0.84RHHBY Roche HoldingPairCorr

Moving against Bayer Pink Sheet

  0.89LLY Eli Lilly And Sell-off TrendPairCorr
  0.86PPERY Bank Mandiri PerseroPairCorr
  0.78PPERF Bank Mandiri PerseroPairCorr
  0.76BKRKY Bank RakyatPairCorr
  0.71MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
The ability to find closely correlated positions to Bayer Aktiengesellscha could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer Aktiengesellscha when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer Aktiengesellscha - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer Aktiengesellschaft to buy it.
The correlation of Bayer Aktiengesellscha is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer Aktiengesellscha moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer Aktiengesellschaft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer Aktiengesellscha can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bayer Aktiengesellschaft. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Bayer Aktiengesellschaft information on this page should be used as a complementary analysis to other Bayer Aktiengesellscha's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Bayer Pink Sheet analysis

When running Bayer Aktiengesellscha's price analysis, check to measure Bayer Aktiengesellscha's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bayer Aktiengesellscha is operating at the current time. Most of Bayer Aktiengesellscha's value examination focuses on studying past and present price action to predict the probability of Bayer Aktiengesellscha's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bayer Aktiengesellscha's price. Additionally, you may evaluate how the addition of Bayer Aktiengesellscha to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Global Correlations
Find global opportunities by holding instruments from different markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Stocks Directory
Find actively traded stocks across global markets
Please note, there is a significant difference between Bayer Aktiengesellscha's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bayer Aktiengesellscha is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bayer Aktiengesellscha's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.